Enterprise Value
552.5M
Cash
105.9M
Avg Qtr Burn
-24.26M
Short % of Float
6.98%
Insider Ownership
1.17%
Institutional Own.
81.33%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XERMELO® (telotristat ethyl) Details Carcinoid syndrome diarrhea | Approved Quarterly sales | |
Sotagliflozin (SGLT1/SGLT2) Details Heart disease, Heart failure Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
Sotagliflozin (Zynquista) (SGLT1/SGLT2) Details Type 1 diabetes, Diabetes | NDA Resubmission | |
LX9211 Details Neuropathy, Diabetic peripheral neuropathy, Postherpetic neuralgia | Phase 2 Update |